Today is the day of the official launch of Chadi’s first book “Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice.” Throughout the book, Chadi details his experience as an expert physician witness and the true story of the first three litigation trials against Monsanto and their herbicide “Roundup” which is linked to the development of Non-Hodgkin Lymphoma.
The special guest on this unique day is the amazing icon and legend Dr. Nassim Nicholas Taleb. Nassim is beyond introduction; a best selling author of several books that contain concepts being taught in many schools. Nassim understands risk like no other and he is famous for predicting the Wall Street crash of 2008. Nassim found himself in the crosshairs with Monsanto, a story that he shares on the podcast.
Dr. Taleb read “Toxic Exposure,” generously offered his opinion, and shared that he liked it and that he would recommend it to his colleagues and followers. They talk about many things, from GMOs to ghostwriting and some of the finer details of the way Monsanto cherry-picked research to fit its arguments as well as how Chadi handled himself throughout the trials.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
